Eli Lilly (LLY) stock has continued its gradual ascent this month, building on a year marked by steady performance. Investors ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U. Food and Drug Administration's new national priority voucher, suggesting it is a strong candidate for a ...

Takeda tightened its pipeline in the third quarter. Innovent Biologics reported a head-to-head win against semaglutide in a Chinese phase 3 trial. | Takeda tightened its pipeline in the third quarter.

Novo Nordisk faces headwinds from regulatory uncertainty, competitive efficacy gaps with Eli Lilly and technical downward ...

Walmart will offer in‑store pickup of Eli Lilly’s discounted weight‑loss drug Zepbound, giving self‑pay customers easier, ...

CEO David Ricks wants Eli Lilly’s upcoming obesity pill to be accessible to patients who need it, but the company still needs ...

Eli Lilly raised its full-year profit and revenue forecasts on Thursday as strong overseas demand for weight-loss and ...

Lilly appears to have triumphed over Novo Nordisk in the battle for the weight-loss market. While both stocks are down from ...

Eli Lilly is partnering with Walmart to offer Zepbound through its direct-to-consumer program, making the popular medication ...

Eli Lilly and Company and Walmart have announced a partnership to offer Zepbound single-dose vials at Walmart pharmacies. The ...

Eli Lilly partners with NVIDIA to build a powerful AI supercomputer and teams up with Walmart to expand affordable Zepbound access nationwide.